LGDN Stock Overview
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Ligand Pharmaceuticals Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$72.50 |
| 52 Week High | US$82.00 |
| 52 Week Low | US$47.00 |
| Beta | 0.92 |
| 1 Month Change | 9.85% |
| 3 Month Change | 10.69% |
| 1 Year Change | 4.32% |
| 3 Year Change | -41.93% |
| 5 Year Change | -34.27% |
| Change since IPO | -12.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| LGDN | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.3% | -3.3% | -1.5% |
| 1Y | 4.3% | -30.8% | 0.9% |
Return vs Industry: LGDN exceeded the German Pharmaceuticals industry which returned -31.3% over the past year.
Return vs Market: LGDN exceeded the German Market which returned -0.4% over the past year.
Price Volatility
| LGDN volatility | |
|---|---|
| LGDN Average Weekly Movement | 6.5% |
| Pharmaceuticals Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: LGDN has not had significant price volatility in the past 3 months.
Volatility Over Time: LGDN's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 58 | Scott Plesha | www.ligand.com |
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19.
Ligand Pharmaceuticals Incorporated Fundamentals Summary
| LGDN fundamental statistics | |
|---|---|
| Market cap | €1.31b |
| Earnings (TTM) | €50.56m |
| Revenue (TTM) | €123.37m |
25.9x
P/E Ratio10.6x
P/S RatioIs LGDN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LGDN income statement (TTM) | |
|---|---|
| Revenue | US$131.31m |
| Cost of Revenue | US$35.05m |
| Gross Profit | US$96.27m |
| Other Expenses | US$42.45m |
| Earnings | US$53.82m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.04 |
| Gross Margin | 73.31% |
| Net Profit Margin | 40.99% |
| Debt/Equity Ratio | 0% |
How did LGDN perform over the long term?
See historical performance and comparison